Table 2.
Characteristics of 538 patients with HBV infection and Advanced-Stage Cancer included in Review
| Characteristic | No | % |
|---|---|---|
| Age, mean(range) | 58.5(16-88) | |
| Sex | ||
| Male | 385 | 72% |
| Female | 103 | 19% |
| Unknown | 50 | 9% |
| Disease type (n=538) | ||
| NSCLC | 70 | 13.0% |
| Melanoma | 46 | 8.6% |
| HCC | 353 | 65.6% |
| Lymphoma | 9 | 1.7% |
| NPC | 35 | 6.5% |
| Other | 25 | 4.6% |
| ICI treatment (n=538) | ||
| Nivolumab | 144 | 80.4% |
| Pembrolizumab | 110 | 61.5% |
| Ipilimumab | 9 | 5.0% |
| Pembrolizumab+Ipilimumab | 4 | 2.2% |
| Atezolizumab | 3 | 1.7% |
| Durvalumab | 1 | 0.6% |
| Ipilimumab+Nivolumab | 2 | 1.1% |
| Sintilimab | 36 | 20.1% |
| Camrelizumab | 13 | 7.3% |
| Toripalimab | 59 | 33.0% |
| Anti-PD-1/PDL-1(not specified) | 114 | 21.2% |
| Anti-PD-1 (not specified) | 43 | 8.05 |
| Baseline viral load recorded (n=444) | ||
| Undetectable | 237 | 53.4% |
| Detectable | 176 | 39.6% |
| Unknown | 31 | 7.0% |
| Antiviral prophylaxis (n=416) | ||
| Entecavir | 240 | 57.7% |
| Tenofovir | 65 | 15.6% |
| Lamivudine | 13 | 3.1% |
| Telbivudine | 1 | 0.2% |
| Adefovir | 1 | 0.2% |
| Unknown | 96 | 23.1% |